JPH1073597A - Method for detecting or measuring immunological active substance - Google Patents

Method for detecting or measuring immunological active substance

Info

Publication number
JPH1073597A
JPH1073597A JP23182896A JP23182896A JPH1073597A JP H1073597 A JPH1073597 A JP H1073597A JP 23182896 A JP23182896 A JP 23182896A JP 23182896 A JP23182896 A JP 23182896A JP H1073597 A JPH1073597 A JP H1073597A
Authority
JP
Japan
Prior art keywords
voltage
reagent
latex
added
carrier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP23182896A
Other languages
Japanese (ja)
Inventor
Keisuke Iwata
恵助 岩田
Yoshinori Yoshimura
佳典 吉村
Masao Karube
征夫 軽部
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A & T Kk
Tokuyama Corp
Original Assignee
A & T Kk
Tokuyama Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & T Kk, Tokuyama Corp filed Critical A & T Kk
Priority to JP23182896A priority Critical patent/JPH1073597A/en
Publication of JPH1073597A publication Critical patent/JPH1073597A/en
Withdrawn legal-status Critical Current

Links

Abstract

PROBLEM TO BE SOLVED: To perform highly sensitive detection quickly by applying the minute voltage of AC or DC on reagent, wherein antigen or antibody is immunized on the carrier of a specified particle diameter. SOLUTION: Immunological active substance is selected from the material, wherein latex or the like is used as a carrier by immunological aggregation reaction, and e.g. infection marker such as CRP, solidifying-line melting-system marker such as D-dimer, tumor marker such as AFP and the like are used. When latex or the like is used as the carrier particles, it is recommendable that the average particle diameter is about 0.01-1μm. As the minute voltage, the AC voltage is recommendable. The voltage in the range, wherein a reaction system does not cause electrolysis, is used. The detecting method is as follows. The specimen is added to the solution, wherein buffer is the main component and processed at the specified temperature and time. Then, after the reagent, wherein antigen is sensitized to the antibody, is added, the suspension of the reagent is added into the solution, wherein the buffer is the main component. Processing is performed at the specified temperature and time. After the specimen is added and the minute voltage is applied, the change in turbidity is measured.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は担体粒子を用いた免
疫学的凝集反応により、免疫学的反応性物質を検出又は
測定する方法に関する。更に詳しくは、該反応系に交流
及び/又は直流に由来する微小電圧を印加することによ
り、免疫学的反応性物質を迅速且つ簡便に、しかも高感
度で検出又は測定する方法に関する。
The present invention relates to a method for detecting or measuring an immunologically reactive substance by an immunological agglutination reaction using carrier particles. More specifically, the present invention relates to a method for rapidly or simply detecting and measuring an immunologically reactive substance with high sensitivity by applying a small voltage derived from alternating current and / or direct current to the reaction system.

【0002】[0002]

【従来の技術】免疫学的反応性物質は、免疫学的凝集反
応により、不溶性凝集塊を形成するのでこれを検出する
ことにより、免疫学的反応性物質を検出又は測定するこ
とが可能である。免疫学的反応性物質を検出又は測定す
る方法として、例えば酵素免疫測定法、放射線免疫測定
法が従来から用いられている。これらの方法は高感度で
あり精度も高い。しかし、酵素や放射線を使用するため
試薬が不安定であることや保管・保存上の規制があるこ
とから、測定において細かい配慮や技術、特別な設備等
が要求されるので、より簡便な方法が求められていた。
また、これらの方法は測定に時間を要するため、緊急検
査においては対処が困難とされ、高感度且つ迅速な方法
が盛んに研究されるようになった。
2. Description of the Related Art An immunologically reactive substance forms an insoluble aggregate by an immunological agglutination reaction, and by detecting this, it is possible to detect or measure the immunologically reactive substance. . As a method for detecting or measuring an immunologically reactive substance, for example, an enzyme immunoassay and a radioimmunoassay have been conventionally used. These methods have high sensitivity and high accuracy. However, because reagents are unstable due to the use of enzymes and radiation, and there are restrictions on storage and storage, detailed considerations, techniques, and special equipment are required for measurement. Was sought.
In addition, since these methods require time for measurement, it is difficult to deal with them in an emergency test, and high-sensitivity and quick methods have been actively studied.

【0003】1970年以降、ラテックス、リポソーム
等の担体を用いた免疫学的凝集反応を測定する方法とし
て光学的分析法(比濁法やカウンティング法)が開発さ
れている。これら免疫学的凝集反応は、一般に撹拌翼等
で撹拌されることにより開始され、37℃〜45℃の温
度下で行われる。このとき測定(反応)に要する時間は
5〜20分である。これは酵素免疫測定や放射線免疫測
定に比べ迅速であるが、測定感度・特異性等において、
段階的に改善されつつあるものの前記方法に劣り、応用
範囲が限定される。
[0003] Since 1970, an optical analysis method (turbidimetry or counting method) has been developed as a method for measuring immunological agglutination using a carrier such as latex or liposome. These immunological agglutination reactions are generally started by stirring with a stirring blade or the like, and are performed at a temperature of 37 ° C to 45 ° C. At this time, the time required for the measurement (reaction) is 5 to 20 minutes. This is quicker than enzyme immunoassay or radioimmunoassay, but in terms of measurement sensitivity and specificity,
Although it is being improved step by step, it is inferior to the above method and its application range is limited.

【0004】該反応系に直流パルスや交流電圧を印加す
ることによって、免疫学的凝集反応を迅速に、しかも高
感度で測定する方法が知られている。例えば民谷らによ
るBiosensors、3(3)、139−146頁(198
8)には、ヒト免疫グロブリンGを1.0μmラテック
ス粒子に結合させた試薬と免疫グロブリンGを電極を備
えたセルにて混合後、波高値200V(電界強度200
V/mm)の直流パルス電圧を印加して、10分後に5
0%の凝集度が得られたと記載されている。また、特開
平7−83928号公報では、10mM以上の塩の共存
下に5〜50V/mmの電界強度になるように交流電圧
を該反応系に印加する方法を提案している。いずれも、
これら変動する電圧を印加することによって、担体粒子
のパールチェイン化により、凝集塊の形成を促進させる
効果による。
There is known a method for measuring an immunological agglutination reaction quickly and with high sensitivity by applying a DC pulse or an AC voltage to the reaction system. For example, Biosensors by Tamiya et al., 3 (3), pp. 139-146 (198)
8) In a cell equipped with electrodes, a reagent in which human immunoglobulin G was bound to 1.0 μm latex particles and immunoglobulin G were mixed, and the peak value was 200 V (electric field intensity 200
V / mm) and a DC pulse voltage of
It is stated that a cohesion of 0% was obtained. Japanese Patent Application Laid-Open No. 7-83928 proposes a method in which an alternating voltage is applied to the reaction system so that the electric field strength becomes 5 to 50 V / mm in the presence of a salt of 10 mM or more. In each case,
By applying these fluctuating voltages, the carrier particles are formed into pearl chains, thereby promoting the formation of aggregates.

【0005】[0005]

【発明が解決すべき課題】しかしながら、免疫学的凝集
反応に汎用されているラテックス試薬(粒子径1μm未
満)では、パールチェイン化は困難であり、高感度化は
期待できない。前記特許公開公報にも、好ましい担体粒
子の平均径は0.5〜10μmと記載されている。本発
明者らは、一般に高感度で迅速且つ簡便であると評価さ
れているラテックス比濁法に使用されている0.1〜0.
5μmの担体粒子からなる試薬を用いて、従来法よりも
更に迅速に、しかも高感度で免疫学的反応性物質を検出
又は測定する方法を知見し、本発明に到達した。
However, it is difficult to form a pearl chain with a latex reagent (particle size less than 1 μm) generally used for immunological agglutination, and high sensitivity cannot be expected. The above-mentioned patent publication also describes that the preferable average diameter of the carrier particles is 0.5 to 10 μm. The present inventors have found that the 0.1 to 0.1 used in latex turbidimetry, which is generally evaluated as being highly sensitive, rapid and simple.
The present inventors have found a method for detecting or measuring an immunologically reactive substance with higher sensitivity and higher sensitivity than the conventional method using a reagent consisting of 5 μm carrier particles, and have reached the present invention.

【0006】[0006]

【課題を解決するための手段】すなわち、本発明は、担
体に抗原若しくは抗体を感作した試薬を用いて、免疫学
的凝集反応により免疫学的反応性物質を検出又は測定す
る方法であって、該反応系に交流及び/又は直流に由来
する微小電圧を印加すること特徴とする方法である。本
発明において、免疫学的凝集反応とは、抗原抗体反応、
特異的レセプターとの反応等を利用した方法であり、定
性法及び定量法の両方を含むものである。本発明におけ
る免疫学的反応性物質は、上記の免疫学的凝集反応によ
って、ラテックス、リポソーム等を担体として使用する
凝集法で測定され得る物質から選択できる。例えばCR
P、HBs抗原、HBs抗体、HCV抗体、HIV抗
体、TP抗体等の感染症マーカー、D−ダイマー、プロ
テインC、プロテインS、ATIII等の凝固線溶系マー
カー、AFP、CEA、CA19−9等の腫瘍マーカ
ー、TSH、プロラクチン、インスリン等のホルモン、
β2m、ミオグロビン、ミオシン等の組織成分、DNA
等の核酸が挙げられる。また、検出可能な濃度は、概ね
0.05ng/ml〜50μg/ml、好ましくは0.1
ng/ml〜10μg/mlである。感作する抗原若し
くは担体としては、上記免疫学的反応性物質を免疫学的
に認識し得る抗原又は抗体を用いる。
That is, the present invention relates to a method for detecting or measuring an immunologically reactive substance by immunological agglutination using a reagent obtained by sensitizing a carrier to an antigen or an antibody. And applying a minute voltage derived from alternating current and / or direct current to the reaction system. In the present invention, the immunological agglutination is an antigen-antibody reaction,
This method utilizes the reaction with a specific receptor, etc., and includes both qualitative and quantitative methods. The immunologically reactive substance in the present invention can be selected from substances that can be measured by the above-described immunological agglutination reaction by an agglutination method using latex, liposome, or the like as a carrier. For example, CR
P, HBs antigen, HBs antibody, HCV antibody, HIV antibody, infectious disease marker such as TP antibody, coagulation / fibrinolytic marker such as D-dimer, protein C, protein S, ATIII, tumor such as AFP, CEA, CA19-9 Markers, hormones such as TSH, prolactin, and insulin,
Tissue components such as β2m, myoglobin and myosin, DNA
And the like. The detectable concentration is generally about 0.05 ng / ml to 50 μg / ml, preferably 0.1 ng / ml.
ng / ml to 10 μg / ml. As the antigen or carrier to be sensitized, an antigen or antibody capable of immunologically recognizing the above immunologically reactive substance is used.

【0007】本発明の担体粒子としては、ラテックス、
リポソーム、金コロイド等が挙げられるが、好ましくは
ラテックス粒子である。ラテックス粒子としては、一般
に免疫学的凝集法に用いられているものが使用できる。
担体粒子の平均径は、ラテックス粒子の場合、0.01
〜1μmが好ましい。より好ましくは0.05〜0.5μ
mである。最も好ましくは0.1〜0.3μmである。平
均径が1μmを超えると粒子のブラウン運動等が起こり
にくくなるので好ましくない。ラテックス粒子への抗体
若しくは抗原の感作は、例えば従来周知の方法で吸着又
は結合させることにより実施することができる。
[0007] The carrier particles of the present invention include latex,
Liposomes, colloidal gold and the like can be mentioned, but latex particles are preferred. As the latex particles, those generally used in an immunological agglutination method can be used.
The average diameter of the carrier particles is 0.01 in the case of latex particles.
11 μm is preferred. More preferably 0.05-0.5μ
m. Most preferably, it is 0.1 to 0.3 μm. When the average diameter exceeds 1 μm, Brownian motion of the particles and the like hardly occur, which is not preferable. The sensitization of the latex particles with the antibody or antigen can be carried out, for example, by adsorbing or binding by a conventionally well-known method.

【0008】本発明の微小電圧は交流及び/又は直流に
由来するものであり、より好ましくは交流電圧である。
直流電圧は電気分解を容易に誘発するので、指摘条件の
範囲が狭まる。また、反応系が電気分解を実質的に起こ
さない範囲の電圧、例えば反応系の電気伝導度が17.
4mS/cm(生理食塩水相当)のとき、電界強度7.
8V/mm以下の交流電圧(周波数10KHz)であ
る。交流電圧の印加時間は、反応系が電気分解を実質的
に起こさない範囲でなるべく長時間印加した方が好まし
く、十数秒〜数分間である。より好ましくは30秒〜2
分間の印加である。しかし、電気分解の起因は、反応系
試液の電気伝導度及び印加電圧、電極の材質、面積、印
加時間等の要因で異なるため、前記した交流電圧の電界
強度、印加時間は実験条件により変動する。
[0008] The minute voltage of the present invention is derived from AC and / or DC, and is more preferably an AC voltage.
DC voltage readily induces electrolysis, thus narrowing the range of indicated conditions. Further, a voltage in a range where the reaction system does not substantially cause electrolysis, for example, the electric conductivity of the reaction system is 17.
At 4 mS / cm (equivalent to physiological saline), the electric field strength is 7.
AC voltage (frequency 10 KHz) of 8 V / mm or less. The application time of the AC voltage is preferably as long as possible within a range in which the reaction system does not substantially cause electrolysis, and is preferably several tens seconds to several minutes. More preferably 30 seconds to 2
Min application. However, the cause of the electrolysis depends on factors such as the electrical conductivity and applied voltage of the reaction system reagent, the material of the electrode, the area, and the application time. .

【0009】本発明の交流の周波数は、検討した範囲内
では免疫学的凝集反応の速度に大きく影響しないが、好
ましくは1KHz〜1MHzの周波数である。本発明に
おける交流電圧の波形は連続波、パルス波のいずれであ
ってもよく、また任意の形状とし得るが、好ましくは正
弦波、方形波、矩形波である。
The alternating current frequency of the present invention does not greatly affect the speed of immunological agglutination within the range studied, but is preferably a frequency of 1 KHz to 1 MHz. The waveform of the AC voltage in the present invention may be any of a continuous wave and a pulse wave, and may have an arbitrary shape, but is preferably a sine wave, a square wave, or a rectangular wave.

【0010】本発明において試薬に微小電圧を印加する
代表的な装置、並びに免疫学的反応性物質を検出又は測
定する代表的な測定装置は、例えば図1(または図5)
に示すように、直流パルス電圧、交流電圧、直流電圧等
の任意電圧が印加できる電源装置、分光光度計用セルに
電極を貼り付けた電極付きセル、電圧、周波数、パルス
幅をモニタするためのオシロスコープ、濁度測定を行う
分光光度計等からなる。電源装置としては、任意のパル
ス発生装置、例えば市販のファンクションジェネレータ
や細胞刺激装置等を使用することができる。分光光度計
用セルとしては、市販のガラスセル、プラスチックセル
等を用いることができ、電極材料としては、白金、ニッ
ケル等を用いることができる。
In the present invention, a typical apparatus for applying a minute voltage to a reagent and a typical measuring apparatus for detecting or measuring an immunologically reactive substance are described, for example, in FIG. 1 (or FIG. 5).
As shown in the figure, a power supply device that can apply any voltage such as a DC pulse voltage, an AC voltage, and a DC voltage, a cell with electrodes in which electrodes are attached to a cell for a spectrophotometer, and a voltage / frequency / pulse width monitor. It consists of an oscilloscope, a spectrophotometer for measuring turbidity, and the like. As the power supply device, an arbitrary pulse generator, for example, a commercially available function generator or cell stimulator can be used. As a spectrophotometer cell, a commercially available glass cell, plastic cell, or the like can be used, and as an electrode material, platinum, nickel, or the like can be used.

【0011】免疫学的反応性物質の存在を検出又は測定
する方法としては、検体を緩衝液を主成分とする溶液に
加え、室温〜37℃で、0.5〜3分間処理し、次いで
担体に抗原若しくは抗体を感作した試薬の懸濁液を加え
た後、或いは上記試薬の懸濁液を緩衝液を主成分とする
溶液に加え、室温〜37℃で、0.5〜3分間処理し、
次いで検体を加えた後、微小電圧を印加しながら若しく
は微小電圧を印加した後、例えば前出の測定装置を用い
て濁度変化量を求める方法により実施される。後者の試
薬を含む溶液に検体を加える方法では、微小電圧を印加
しながら検体を加えた後に濁度変化を測定することもで
きる。
As a method for detecting or measuring the presence of an immunologically reactive substance, a sample is added to a buffer-based solution, treated at room temperature to 37 ° C. for 0.5 to 3 minutes, and then treated with a carrier. After adding a suspension of a reagent sensitized with an antigen or an antibody to the solution, or adding the suspension of the above reagent to a solution containing a buffer as a main component, and treating at room temperature to 37 ° C. for 0.5 to 3 minutes. And
Then, after adding a specimen, while applying a minute voltage or after applying a minute voltage, the method is carried out by, for example, a method of calculating a turbidity change amount using the above-described measuring device. In the latter method of adding a sample to a solution containing a reagent, a change in turbidity can be measured after applying the sample while applying a minute voltage.

【0012】本発明に用いられる試薬は、通常、水系媒
体中に分散して用いられる。試薬を含む水系媒体中の塩
濃度は特に規定されないが、好ましくは電気伝導度0〜
100mS/cmである。より好ましくは2〜60mS
/cmである。塩としては、例えば塩化カリウム、塩化
ナトリウム、硝酸ナトリウム、硝酸アンモニウム等が挙
げられるが、特に塩化カリウム、塩化ナトリウムが好ま
しい。試薬を含む水系媒体の組成としては、当業者によ
く知られている組成が使用できる。例えばアルブミン等
のタンパク、ポリエチレングリコール、ツイーン、トラ
イトン等の界面活性剤、塩化コリン等の塩化物、アルギ
ニン、アスパラギン等のアミノ酸類、アジ化ナトリウム
等の防腐剤等が添加されていてもよい。反応系の電気伝
導度は小さい方が好ましく、電気伝導度が小さくなると
該反応系に印加できる電界強度を大きくできるので免疫
学的凝集反応の促進効果が得られ易く望ましい。
The reagent used in the present invention is usually used by dispersing it in an aqueous medium. The salt concentration in the aqueous medium containing the reagent is not particularly limited, but is preferably 0 to 0.
100 mS / cm. More preferably, 2 to 60 mS
/ Cm. Examples of the salt include potassium chloride, sodium chloride, sodium nitrate, ammonium nitrate and the like, and potassium chloride and sodium chloride are particularly preferable. As a composition of the aqueous medium containing the reagent, a composition well known to those skilled in the art can be used. For example, proteins such as albumin, surfactants such as polyethylene glycol, Tween and Triton, chlorides such as choline chloride, amino acids such as arginine and asparagine, and preservatives such as sodium azide may be added. It is preferable that the electric conductivity of the reaction system is small. If the electric conductivity is low, the intensity of the electric field that can be applied to the reaction system can be increased, so that the effect of promoting the immunological agglutination reaction can be easily obtained.

【0013】[0013]

【実施例】以下、実施例及び比較例をもって本発明を詳
細に説明するが、これらは本発明を限定するものではな
い。
EXAMPLES The present invention will be described in detail below with reference to examples and comparative examples, but these do not limit the present invention.

【0014】実施例1 交流電圧特性/印加電圧電界強
度 (1) AFPラテックス試薬の調製 5mgの抗AFP抗体を9.5mlのグリシン緩衝液
(以下GBSと略す)に溶解し、0.5mlのラテック
ス(粒子径0.22μm、固形分10%懸濁液)を加
え、室温で2時間撹拌した後、感作したラテックス懸濁
液を遠心分離して上清を除去した。沈殿を33mlの
0.2%BSA−GBSに懸濁させ、AFPラテックス
試薬を調製した。
Example 1 AC voltage characteristics / applied voltage electric field strength (1) Preparation of AFP latex reagent 5 mg of anti-AFP antibody was dissolved in 9.5 ml of glycine buffer (hereinafter abbreviated as GBS), and 0.5 ml of latex was dissolved. (Particle size: 0.22 μm, solid content: 10% suspension) was added, and the mixture was stirred at room temperature for 2 hours, and the sensitized latex suspension was centrifuged to remove the supernatant. The precipitate was suspended in 33 ml of 0.2% BSA-GBS to prepare an AFP latex reagent.

【0015】(2) 交流電圧印加装置 図1の実験装置を使用して、オシロスコープにより電極
間にかかる電位の条件を設定して交流電圧を印加した。
(電極間の距離3mm) (3)測定方法 電極を張り合わせたガラスセルに0.2%牛血清アルブ
ミンを含有するリン酸緩衝液(15mMリン酸、0.4
%ポリエチレングリコール6000、2%塩化ナトリウ
ム、0.1%アジ化ナトリウム含有、以下0.2%BSA
−PBSと略す)600μl、AFPラテックス試薬3
00μlを分注し、交流(AC)電圧(0V〜±7.5
V、周波数10KHz、正弦波)を2分間印加した。印
加開始30秒後に、検体60μlを添加した後、直ちに
分光光度計(日立U−3200)を用いて濁度変化のタ
イムコースを測定し、5分間の濁度差(ΔOD 572
nm)を求めた。なお、0.2%BSA−GBSを用い
て、AFP標準を希釈してAFP濃度0〜2.5ng/
mlの検体を調整し測定に使用した。印加電圧の電界強
度を0V、±1V、±3.5V、±4.5V、±7.5V
に設定して、各濃度の検体を測定した。
(2) AC Voltage Applying Apparatus Using the experimental apparatus shown in FIG. 1, an oscilloscope was used to set the condition of the potential applied between the electrodes and apply an AC voltage.
(Distance between electrodes: 3 mm) (3) Measurement method Phosphate buffer (15 mM phosphoric acid, 0.4 mM) containing 0.2% bovine serum albumin in a glass cell with electrodes attached
% Polyethylene glycol 6000, 2% sodium chloride, 0.1% sodium azide, below 0.2% BSA
-PBS) 600 μl, AFP latex reagent 3
Dispense 00 μl, and apply an alternating current (AC) voltage (0 V to ± 7.5
V, frequency 10 KHz, sine wave) for 2 minutes. Thirty seconds after the start of the application, 60 μl of the sample was added, and the time course of turbidity change was immediately measured using a spectrophotometer (Hitachi U-3200), and the turbidity difference (ΔOD572) for 5 minutes was measured.
nm). The AFP standard was diluted with 0.2% BSA-GBS to obtain an AFP concentration of 0 to 2.5 ng /.
A sample of ml was prepared and used for measurement. Electric field strength of applied voltage is 0V, ± 1V, ± 3.5V, ± 4.5V, ± 7.5V
And the sample of each concentration was measured.

【0016】(4) 結果 結果を表1および図2に示した。図2から明らかなよう
に、本発明によれば、従来法(印加電圧0V)に比べ、
免疫学的凝集反応を促進化させて高感度に免疫学的反応
性物質を検出又は測定することが可能であることが分か
る。また、印加電圧の電界強度を大きくした方が、免疫
学的凝集反応をより促進化できることが分かる。
(4) Results The results are shown in Table 1 and FIG. As is clear from FIG. 2, according to the present invention, compared to the conventional method (applied voltage 0 V),
This shows that it is possible to detect or measure an immunologically reactive substance with high sensitivity by promoting an immunological agglutination reaction. Also, it can be seen that increasing the electric field strength of the applied voltage can further promote the immunological agglutination reaction.

【0017】[0017]

【表1】 [Table 1]

【0018】実施例2 交流電圧特性/周波数 (1) AFPラテックス試薬の調製 実施例1と同様して、AFPラテックス試薬を調製し
た。 (2) 交流電圧印加装置 実施例1と同様の装置で測定した。 (3) 測定方法 周波数10Hz〜100KHzの交流電圧(正弦波)を
電界強度±6Vとなるように印加し、実施例1と同様に
して、各検体の周波数に対する濁度変化を測定した。 (4) 結果 結果を表2および図3に示した。図3に示した結果か
ら、交流周波数は1〜100KHzの間では、免疫学的
凝集反応を一様に促進化できることが分かる。
Example 2 AC voltage characteristics / frequency (1) Preparation of AFP latex reagent An AFP latex reagent was prepared in the same manner as in Example 1. (2) AC voltage application device The measurement was performed using the same device as in Example 1. (3) Measurement method An alternating voltage (sine wave) having a frequency of 10 Hz to 100 KHz was applied so that the electric field strength became ± 6 V, and the turbidity change with respect to the frequency of each sample was measured in the same manner as in Example 1. (4) Results The results are shown in Table 2 and FIG. From the results shown in FIG. 3, it can be seen that the immunological agglutination reaction can be uniformly promoted when the AC frequency is between 1 and 100 KHz.

【0019】[0019]

【表2】 [Table 2]

【0020】実施例3 交流電圧特性/印加時間 (1) AFPラテックス試薬の調製 実施例1と同様して、AFPラテックス試薬を調製し
た。 (2) 交流電圧印加装置 実施例1と同様の装置で測定した。 (3) 測定方法 電界強度±7.5V、周波数10KHzの交流電圧(正
弦波)を0〜4分間印加し、実施例1と同様にして、各
検体の印加時間に対する濁度変化を測定した。 (4) 結果 結果を表3および図4に示した。図4に示した結果か
ら、交流電圧の印加時間を長くした方が、免疫学的凝集
反応をより促進化できることが分かる。
Example 3 AC voltage characteristics / application time (1) Preparation of AFP latex reagent In the same manner as in Example 1, an AFP latex reagent was prepared. (2) AC voltage application device The measurement was performed using the same device as in Example 1. (3) Measurement method An alternating voltage (sine wave) having an electric field strength of ± 7.5 V and a frequency of 10 KHz was applied for 0 to 4 minutes, and the turbidity change with respect to the application time of each sample was measured in the same manner as in Example 1. (4) Results The results are shown in Table 3 and FIG. From the results shown in FIG. 4, it can be seen that the longer the application time of the AC voltage, the more the immunological agglutination reaction can be promoted.

【0021】[0021]

【表3】 [Table 3]

【0022】実施例4 (1) AFPラテックス試薬の調製 実施例1と同様して、AFPラテックス試薬を調製し
た。 (2) 直流電圧印加装置 図5の実験装置を使用して、オシロスコープにより電極
間にかかる電位の条件を設定して直流電圧を印加した。
(電極間3mm) (3) 測定方法 電極を張り合わせたガラスセルに0.2%BSA−PB
S600μl、AFPラテックス試薬300μlを分注
し、直流電圧1Vを50秒間印加した。印加開始10秒
後に、検体60μlを添加した後、直ちに分光光度計
(日立U−3200)を用いて濁度測定し、更に5分後
に撹拌した後、濁度測定を行い5分間の濁度差(ΔOD
572nm)を求めた。なお、0.2%BSA−GB
Sを用いて、AFP標準を希釈してAFP濃度0〜1.
25ng/mlの検体を調整し測定に使用した。 (4) 結果 結果を表4および図6に示した。図6に示した結果か
ら、本発明方法によれば、従来法(印加電圧0V)に比
べ免疫学的凝集反応を促進させ、高感度に免疫学的反応
性物質を検出又は測定することが可能であることがわか
る。
Example 4 (1) Preparation of AFP Latex Reagent AFP latex reagent was prepared in the same manner as in Example 1. (2) DC voltage applying device Using the experimental device of FIG. 5, a DC voltage was applied by setting the condition of the potential applied between the electrodes using an oscilloscope.
(3 mm between electrodes) (3) Measurement method 0.2% BSA-PB was placed in a glass cell with electrodes attached.
S600 μl of SFP and 300 μl of AFP latex reagent were dispensed, and a DC voltage of 1 V was applied for 50 seconds. Ten seconds after the start of the application, 60 μl of the sample was added, and the turbidity was measured immediately using a spectrophotometer (Hitachi U-3200). After stirring for 5 minutes, the turbidity was measured and the turbidity difference was measured for 5 minutes. (ΔOD
572 nm). In addition, 0.2% BSA-GB
Using S, dilute the AFP standard to give an AFP concentration between 0 and 1.
A sample of 25 ng / ml was prepared and used for measurement. (4) Results The results are shown in Table 4 and FIG. From the results shown in FIG. 6, according to the method of the present invention, the immunological agglutination reaction is promoted as compared with the conventional method (applied voltage of 0 V), and the immunologically reactive substance can be detected or measured with high sensitivity. It can be seen that it is.

【0023】[0023]

【表4】 [Table 4]

【0024】[0024]

【発明の効果】本発明によれば、従来の測定方法よりも
短時間に、しかも高感度で免疫学的反応性物質を検出又
は測定することができる。
According to the present invention, it is possible to detect or measure an immunologically reactive substance in a shorter time and with higher sensitivity than the conventional measurement method.

【図面の簡単な説明】[Brief description of the drawings]

【図1】本発明の実施例で使用した交流電圧印加実験装
置の概略図である。
FIG. 1 is a schematic diagram of an AC voltage application experimental device used in an example of the present invention.

【図2】ヒトAFP濃度、交流電圧の印加と濁度変化と
の関係を表したグラフである。
FIG. 2 is a graph showing the relationship between human AFP concentration, application of an AC voltage, and turbidity change.

【図3】ヒトAFP濃度、交流電圧の周波数と濁度変化
との関係を表したグラフである。
FIG. 3 is a graph showing a relationship between a human AFP concentration, a frequency of an AC voltage, and a turbidity change.

【図4】ヒトAFP濃度、交流電圧の印加時間と濁度変
化との関係を表したグラフである。
FIG. 4 is a graph showing the relationship among human AFP concentration, AC voltage application time, and turbidity change.

【図5】本発明の実施例で使用した直流電圧印加実験装
置の概略図である。
FIG. 5 is a schematic diagram of a DC voltage application experimental device used in an example of the present invention.

【図6】直流電圧印加によるヒトAFP濃度と濁度変化
との関係を表したグラフである。
FIG. 6 is a graph showing a relationship between a human AFP concentration and a change in turbidity due to application of a DC voltage.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 吉村 佳典 茨城県つくば市千現1−13−7 イーグル 1 201号 (72)発明者 軽部 征夫 神奈川県川崎市宮前区東有馬1−3−16 ──────────────────────────────────────────────────続 き Continued on the front page (72) Inventor Yoshinori Yoshimura 1-1-13-7 Sengen, Tsukuba, Ibaraki Prefecture Eagle 1201 (72) Inventor Masao Karube 1-3-16 Higashiarima, Miyamae-ku, Kawasaki-shi, Kanagawa

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 担体に抗原若しくは抗体を感作した試薬
を用いて、免疫学的凝集反応により免疫学的反応性物質
を検出又は測定する方法であって、該反応系に交流及び
/又は直流に由来する微小電圧を印加することを特徴と
する方法。
1. A method for detecting or measuring an immunologically reactive substance by an immunological agglutination reaction using a reagent sensitized to an antigen or an antibody on a carrier, wherein an alternating current and / or direct current is applied to the reaction system. Applying a minute voltage derived from the method.
【請求項2】 微小電圧は反応系が電気分解を実質的に
起こさない電圧である請求項1の方法。
2. The method according to claim 1, wherein the minute voltage is a voltage at which the reaction system does not substantially cause electrolysis.
【請求項3】 担体の平均粒子径が0.01〜1μmで
ある請求項1の方法。
3. The method according to claim 1, wherein the carrier has an average particle size of 0.01 to 1 μm.
JP23182896A 1996-09-02 1996-09-02 Method for detecting or measuring immunological active substance Withdrawn JPH1073597A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP23182896A JPH1073597A (en) 1996-09-02 1996-09-02 Method for detecting or measuring immunological active substance

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23182896A JPH1073597A (en) 1996-09-02 1996-09-02 Method for detecting or measuring immunological active substance

Publications (1)

Publication Number Publication Date
JPH1073597A true JPH1073597A (en) 1998-03-17

Family

ID=16929664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP23182896A Withdrawn JPH1073597A (en) 1996-09-02 1996-09-02 Method for detecting or measuring immunological active substance

Country Status (1)

Country Link
JP (1) JPH1073597A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005088309A1 (en) * 2004-03-12 2005-09-22 Pulse-Immunotech Corporation Method of measuring affinity substance
EP1637884A1 (en) * 2003-06-16 2006-03-22 Pulse-Immunotech Corporation Method for measuring substance having affinity

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1637884A1 (en) * 2003-06-16 2006-03-22 Pulse-Immunotech Corporation Method for measuring substance having affinity
EP1637884A4 (en) * 2003-06-16 2007-11-14 Pulse Immunotech Corp Method for measuring substance having affinity
WO2005088309A1 (en) * 2004-03-12 2005-09-22 Pulse-Immunotech Corporation Method of measuring affinity substance

Similar Documents

Publication Publication Date Title
EP0019741B1 (en) Latex reagent, process for its preparation, its application and an agent containing this reagent
GB1577956A (en) Determination of proteins
JP2002536660A (en) Enzyme-linked immunomagnetic electrochemical biosensor
JPS6353510B2 (en)
JP2564540B2 (en) Immunoassay method
JP3300493B2 (en) Method for detecting or measuring the presence of a biologically specific reactive substance
US4851329A (en) Immunoassay employing optical pulse particle size analysis
CN112505322A (en) Alzheimer disease marker p-Tau217 detection kit and manufacturing method thereof
JPH1073597A (en) Method for detecting or measuring immunological active substance
JPH1073595A (en) Method for detecting or measuring presence of immunological active substance and reagent used for method thereof
SU1431662A3 (en) Method of producing reagent for effecting agglutination reaction
EP1637884A1 (en) Method for measuring substance having affinity
EP1930725A1 (en) Method of assaying substance with affinity in sample containing blood-cell ingredient
CA2157893A1 (en) Immunoassay method utilizing zeta potential and immunoassay kit
JP3886639B2 (en) Immunological agglutination reagent and method for suppressing prozone phenomenon using the same
JPS6243501B2 (en)
JPH1073596A (en) Method for detecting or measuring immunological active substance
JPH09101307A (en) Method for detecting or measuring immunologically reactive substance
EP1724583A1 (en) Method of measuring affinity substance
JP3618797B2 (en) Immunoassay
Leek et al. Particle counting immunoassay (PACIA) V-its application to the determination of human placental lactogen
JP4288672B2 (en) Method for measuring affinity substances by particle aggregation and dilution
JP3966615B2 (en) Immunological agglutination reagent and method for suppressing prozone phenomenon using the same
JPH09304386A (en) Manufacture of immunity diagnostic drug and immunity diagnostic drug obtained
JP3804817B2 (en) Antibody measuring reagent and production method thereof

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20031104